Cytokinetics CYTK Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's total liabilities & equity?
- Cytokinetics (CYTK) reported total liabilities & equity of $1.27B in Q1 2026.
- How has Cytokinetics's total liabilities & equity changed year-over-year?
- Cytokinetics's total liabilities & equity increased by 0.7% year-over-year, from $1.26B to $1.27B.
- What is the long-term trend for Cytokinetics's total liabilities & equity?
- Over 5 years (2020 to 2025), Cytokinetics's total liabilities & equity has grown at a 21.7% compound annual growth rate (CAGR), from $533.8M to $1.42B.
- What does total liabilities & equity mean?
- The total sum of all money owed and all equity invested in the company.
- How do you interpret total liabilities & equity?
- Growth in this metric indicates the company is expanding its asset base, either through debt financing or equity issuance.
- How does total liabilities & equity compare across companies?
- Used as the denominator for many balance sheet efficiency ratios across the industry.